0001593968-20-002179.txt : 20201110 0001593968-20-002179.hdr.sgml : 20201110 20201110183303 ACCESSION NUMBER: 0001593968-20-002179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201106 FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ignelzi Troy A. CENTRAL INDEX KEY: 0001579829 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 201302457 MAIL ADDRESS: STREET 1: C/O ESPERION THERAPEUTICS, INC. STREET 2: 46701 COMMERCE CENTER DRIVE CITY: PLYMOUTH STATE: MI ZIP: 48170 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 ARCH STREET STREET 2: SUITE 3110 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 33 ARCH STREET STREET 2: SUITE 3110 CITY: BOSTON STATE: MA ZIP: 02110 4 1 primary_01.xml PRIMARY DOCUMENT X0306 4 2020-11-06 0001771917 Karuna Therapeutics, Inc. KRTX 0001579829 Ignelzi Troy A. C/O KARUNA THERAPEUTICS, INC. 33 ARCH ST STE 3110 BOSTON MA 02110-1424 false true false false Chief Financial Officer Common Stock 2020-11-06 4 M false 564 9.2 A 5564 D Common Stock 2020-11-06 4 S false 564 108.15 D 5000 D Common Stock 2020-11-09 4 M false 8000 9.2 A 13000 D Common Stock 2020-11-09 4 S false 8000 105.02 D 5000 D Common Stock 2020-11-09 4 M false 1318 9.2 A 6318 D Common Stock 2020-11-09 4 S false 1318 108.26 D 5000 D Common Stock 2020-11-10 4 M false 118 9.2 A 5118 D Common Stock 2020-11-10 4 S false 118 103.48 D 5000 D Option (right to buy) 9.20 2020-11-06 4 M false 564 0 D 2020-03-01 2029-03-21 Common Stock 564 235230 D Option (right to buy) 9.20 2020-11-09 4 M false 8000 0 D 2020-03-01 2029-03-21 Common Stock 8000 227230 D Option (right to buy) 9.20 2020-11-09 4 M false 1318 0 D 2020-03-01 2029-03-21 Common Stock 1318 225912 D Option (right to buy) 9.20 2020-11-10 4 M false 118 0 D 2020-03-01 2029-03-21 Common Stock 118 225794 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.05 to $109.08, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. /s/ Troy Ignelzi 2020-11-10